NEW YORK (Genomeweb News) – Exiqon announced today that its second quarter revenues increased 15 percent year over year as it significantly trimmed its net loss for the period.

The Danish firm brought in total revenues of DKK 33.3 million ($5.97 million) for the second quarter, up from DKK 29.1 million for Q2 2012. Exiqon said that its research product sales and services revenue was up 21 percent to DKK 26.8 million from DKK 22.2 million.

The firm cut its net loss to DKK 1.3 million, or DKK .03 per share, from DKK 4.1 million, or DKK .12 per share, year over year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: caution urged in use of gene drives, and more.

NIH's Sally Rockey examines the tapped and untapped potential of the NIH peer reviewer pool.

PLOS Biology has asked researchers how they envision the future of genetics and genomics.

Representative Lamar Smith brings back a provision to require the National Science Foundation to certify that each study it funds is "in the national interest."